<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222322</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-05-031</org_study_id>
    <nct_id>NCT04222322</nct_id>
  </id_info>
  <brief_title>The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity With and Without Prediabetes</brief_title>
  <official_title>The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity With and Without Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epitomee medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epitomee medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of Epitomee Capsule on body weight in patients with overweight and obesity with&#xD;
      and without Prediabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Prospective, Randomized, Double-blind, Placebo controlled, Multi-center, Pivotal,&#xD;
      Adaptive trial designed to demonstrate that the use of Epitomee Capsule, in combination with&#xD;
      lifestyle modification, is superior to the placebo device in reducing body weight at 24-weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between the percent body weight loss between the active and control groups</measure>
    <time_frame>24 weeks</time_frame>
    <description>The difference between the percent average body weight loss at 24-weeks post randomization between the active and control groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of treatment responders in the active group</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of treatment responders defined as subjects who have lost 5% or more of baseline weight at 24-weeks post randomization, among the active group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Epitomee Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epitomee Capsule combined with moderate intensity lifestyle counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Visually matching (to Epitomee capsule) placebo capsule combined with moderate intensity lifestyle counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epitomee Capsule</intervention_name>
    <description>Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.</description>
    <arm_group_label>Epitomee Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control-Placebo</intervention_name>
    <description>Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.</description>
    <arm_group_label>Control-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women &gt;= 18 years&#xD;
&#xD;
          2. Current BMI of 25.0-40.0 kg/m2 inclusive&#xD;
&#xD;
          3. Eligible female subjects will be:&#xD;
&#xD;
             Non-pregnant, evidenced by a negative urine dipstick pregnancy test Non-lactating&#xD;
             Females will be either surgically sterile or postmenopausal or agree to continue using&#xD;
             an accepted method of birth control during the study.&#xD;
&#xD;
          4. Normoglycemic subjects with both:&#xD;
&#xD;
               1. Fasting plasma glucose &lt;100 mg/dL&#xD;
&#xD;
               2. HbA1c &lt;5.7% or:&#xD;
&#xD;
             Prediabetic subjects with either one or both of the following criteria:&#xD;
&#xD;
               1. FPG≥100 mg/dL and &lt;126 mg/dL&#xD;
&#xD;
               2. 5.7% ≤ HbA1c ≤6.4% Naive Prediabetes or treated with metformin (up to 2000mg/dL&#xD;
                  inclusive)&#xD;
&#xD;
          5. Ability to provide informed consent before any trial-related activities&#xD;
&#xD;
          6. Ability and willingness to complete the physical activity in accordance to the study's&#xD;
             exercise program&#xD;
&#xD;
          7. Willingness to maintain a diet in accordance with study requirement for the duration&#xD;
             of the study&#xD;
&#xD;
          8. Subjects must have:&#xD;
&#xD;
               -  A primary care provider who is responsible for providing routine care&#xD;
&#xD;
               -  A reliable telephone or internet service to communicate with study staff&#xD;
&#xD;
          9. Understand and be willing to comply with all study-related procedures and agree to&#xD;
             participate in the study by giving written informed consent&#xD;
&#xD;
         10. Study subjects must be willing to notify the staff of any change in their medical&#xD;
             health (including surgeries) or change in drug treatments (addition of drugs, stopping&#xD;
             of drugs, or change in drug dose) during the course of the trial.&#xD;
&#xD;
         11. Previously attempted to lose weight unsuccessfully using a medically supervised or&#xD;
             self-directed diet.&#xD;
&#xD;
         12. Willingness to avoid medications or other substances known to affect weight changes&#xD;
             during the study&#xD;
&#xD;
         13. Willingness to avoid non-steroidal anti-inflammatory drugs (NSAIDs) other than low&#xD;
             dose aspirin including Diclofenac, Ibuprofen, Naproxen, or other medications known to&#xD;
             be gastric irritants during the study.&#xD;
&#xD;
         14. Subjects on psychiatric medications are clinically well-controlled with a stable&#xD;
             psychiatric medication dose for at least 3 months prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing, or plans to become pregnant in the next 12 months, or not using&#xD;
             adequate contraceptive measures&#xD;
&#xD;
          2. Weight loss of more than 10 pounds in the past 6 months&#xD;
&#xD;
          3. Use in the past 6 months of medications or other substances known to induce weight&#xD;
             gain or weight loss&#xD;
&#xD;
          4. Participation in any clinical study (weight-loss or non-weight loss study) within the&#xD;
             past 3 months&#xD;
&#xD;
          5. Known history of endocrine disorders affecting weight, such as uncontrolled abnormal&#xD;
             thyroid function, hypothalamic tumors, Cushing's syndrome, or other genetic syndromes&#xD;
&#xD;
          6. Currently receiving chronic steroid or immunosuppressive therapy&#xD;
&#xD;
          7. Subjects previously diagnosed with HIV, hepatitis B or C&#xD;
&#xD;
          8. Subjects diagnosed with bulimia, binge eating disorder, compulsive overeating, high&#xD;
             liquid calorie intake, or similar eating related psychological disorders&#xD;
&#xD;
          9. Intent to undergo gastric surgery or gastric banding during the study period or within&#xD;
             the 6-month period after completion of this study&#xD;
&#xD;
         10. Prior use of any weight loss gastric medical device such as gastric balloon or gastric&#xD;
             aspiration device&#xD;
&#xD;
         11. Known history of structural or functional disorders of the esophagus that may impede&#xD;
             passage of the device through the gastrointestinal tract, including: Barrett's&#xD;
             esophagus, esophagitis, dysphagia, achalasia, stricture/stenosis, esophageal varices,&#xD;
             esophageal diverticula, esophageal perforation, or any other disorder of the esophagus&#xD;
&#xD;
         12. Known history of any swallowing disorder, esophageal chest pain disorders, or drug&#xD;
             refractory esophageal reflux symptoms&#xD;
&#xD;
         13. Known history of structural or functional disorders of the stomach including, gastric&#xD;
             ulcer, chronic gastritis, gastric varices, hiatal hernia (&gt; 2 cm), cancer or any other&#xD;
             disorder of the stomach or any symptoms of chronic upper abdominal pain, chronic&#xD;
             nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis,&#xD;
             including post-prandial fullness or pain, post-prandial nausea or vomiting or early&#xD;
             satiety.&#xD;
&#xD;
         14. Known history of duodenal ulcer, intestinal diverticula (diverticulitis), intestinal&#xD;
             varices, intestinal stricture/stenosis, small bowel obstruction, or any other&#xD;
             obstructive disorder of the gastrointestinal (GI) tract&#xD;
&#xD;
         15. Currently have ongoing symptoms suggestive of intermittent small bowel obstruction,&#xD;
             such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting&#xD;
&#xD;
         16. Known history of irritable bowel syndrome, radiation enteritis or other inflammatory&#xD;
             bowel disease, such as Crohn's disease&#xD;
&#xD;
         17. Known history of GI surgeries that may have resulted in anatomical GI tract&#xD;
             abnormalities such as a stoma, Nissen Fundoplication or narrowing of any portion of&#xD;
             the digestive tract. Examples of these GI surgeries include, but are not limited to,&#xD;
             gastric banding; however, uncomplicated appendectomies are acceptable. In addition,&#xD;
             known history of any surgeries that may have resulted in anatomical GI tract&#xD;
             abnormalities such intestinal adhesions, or any other condition that may inhibit&#xD;
             passage through any portion of the GI tract must be excluded&#xD;
&#xD;
         18. Subjects with Type 1 diabetes or type 2 diabetes&#xD;
&#xD;
         19. Experienced a myocardial infarction, has a known history of angina, underwent coronary&#xD;
             bypass, a known history of congestive heart failure, or is currently being medically&#xD;
             treated for any other cardiac condition&#xD;
&#xD;
         20. Poorly controlled hypertension (≥ 160 mmHg systolic and ≥ 100mmHg diastolic)&#xD;
&#xD;
         21. End stage renal disease or requiring hemodialysis within the past 6 months&#xD;
&#xD;
         22. Subjects taking medications on specified hourly intervals that may be affected by&#xD;
             changes to gastric emptying, such as anti-seizure or anti-arrhythmic medications&#xD;
&#xD;
         23. Subjects requiring the use of anti-platelet drugs (except for low dose Aspirin as&#xD;
             mentioned above) or other agents affecting the normal clotting of blood&#xD;
&#xD;
         24. Study subjects must not have a history of substance use disorder (licit or illicit)&#xD;
             drug or alcohol abuse/addiction within 5 years of visit #1 (i.e. day of signing the&#xD;
             informed consent document).&#xD;
&#xD;
         25. Study subjects must not have a medical history of sensitivity, intolerance, or&#xD;
             toxicity to the investigational product, or agents similar to the investigational&#xD;
             product.&#xD;
&#xD;
         26. Study subjects must not have a history of anaphylaxis or anaphylactoid reaction to any&#xD;
             prior drug or supplement of any kind.&#xD;
&#xD;
         27. Study subjects must not have a history of cancer with the exception of non-melanoma&#xD;
             skin cancer and &quot;in situ&quot; cancer of the cervix.&#xD;
&#xD;
         28. Study subjects must not be anticipating a significant change in job, job duties, or&#xD;
             job work hours, which might impair their ability and willingness to undergo&#xD;
             study-related procedures under the timelines specified by protocol, and otherwise&#xD;
             impede their completion of the study.&#xD;
&#xD;
         29. Study subjects must not anticipate a reasonable likelihood of moving away from the&#xD;
             research site, wherein such a move might impair their ability and willingness to&#xD;
             undergo study-related procedures within the timelines specified by protocol, or&#xD;
             otherwise impede their completion of the study.&#xD;
&#xD;
         30. Subjects who stopped smoking within 6 months prior to Screening Visit or considering&#xD;
             smoking cessation during the study&#xD;
&#xD;
         31. Subjects who are habitual laxative users or using prescription medication for chronic&#xD;
             constipation&#xD;
&#xD;
         32. Study subjects must not have change in medications treating hypertension and/or&#xD;
             dyslipidemia within 1 month prior to Screening Visit (including change in dose)&#xD;
&#xD;
         33. Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical&#xD;
             condition.&#xD;
&#xD;
         34. Subject is employed by the investigator, or is a close relative of the investigator,&#xD;
             or the investigator's staff&#xD;
&#xD;
         35. Subject is a close relative of another subject already enrolled in the study or lives&#xD;
             in the same home with another subject enrolled in the study.&#xD;
&#xD;
         36. Subjects on psychiatric medications with no lifetime history of suicidal behavior.&#xD;
&#xD;
         37. Any other condition that, in the opinion of the investigator, would interfere with&#xD;
             subject participation, may confound the study results, or interfere with compliance&#xD;
             with the study (e.g., psycho-social issues).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael Kenan, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Epitomee Medical, VP Clinical Affairs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yael Kenan, Dr.</last_name>
    <phone>+972548106398</phone>
    <email>yael.k@epitomeemedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adi Benari</last_name>
    <phone>+972523863087</phone>
    <email>adi@epitomeemedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University - 645 N. Michigan Avenue, Suite 530</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kushner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Kushner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Bays, MD</last_name>
    </contact>
    <investigator>
      <last_name>Harold E Bays, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center , 6400 Perkins Road</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Greenway, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frank Greenway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest School of Medicine, Wake Forest Baptist Health - 525 Vine Street, 5th Floor, Suite 5119</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamy Ard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jamy Ard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Weight and Eating Disorders at Perelman School of Medicine University of Pennsylvania - 3400 Civic Center Boulevard, Building 421,</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wadden</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Wadden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Weight Management Center - 67 President Street, Suite 410 South</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick O'Neil</last_name>
    </contact>
    <investigator>
      <last_name>Patrick O'Neil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

